Nevertheless, descriptive heatmaps for molecular pathways, including angiogenesis and PI3K-AKT-mTOR signaling, known to be involved in RCC, were mandatory for designing specific biomarker or drug testing studies with novel drug candidates. This evidence concerns the gene AKT1 and renal cell carcinoma.